Replimune (REPL) Enterprise Value (2018 - 2026)
Replimune (REPL) reported Enterprise Value of -$268.9 million for Q1 2026, up 44.42% on a YoY basis from -$186.2 million in Q1 2025, and little changed sequentially from -$269.1 million in Q4 2025.
Replimune (REPL) Enterprise Value (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Enterprise Value data on file, last reported at -$268.9 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 44.42% year-over-year to -$268.9 million; the trailing twelve-month figure through Mar 2026 stood at -$268.9 million (up 44.42% YoY), and the FY2026 full-year result was -$268.9 million, up 44.42% from the prior year.
- Enterprise Value was little changed at -$268.9 million in Q1 2026, from -$269.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$268.9 million in Q1 2026 to a low of -$616.4 million in Q4 2022.
- A 5-year average of -$437.7 million and a median of -$432.1 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 59.92% in 2023 and soared 49.84% in 2025, its largest moves.
- Tracing REPL's Enterprise Value over 5 years: stood at -$616.4 million in 2022, then advanced by 24.34% to -$466.4 million in 2023, then declined by 15.05% to -$536.5 million in 2024, then soared by 49.84% to -$269.1 million in 2025, then advanced by 0.09% to -$268.9 million in 2026.
- Business Quant data shows REPL's Enterprise Value at -$268.9 million in Q1 2026, -$269.1 million in Q4 2025, and -$323.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -268.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.89 Mn |
| Dec 31, 2025 | -269.14 Mn |
| Sep 30, 2025 | -323.64 Mn |
| Jun 30, 2025 | -403.34 Mn |
| Mar 31, 2025 | -483.80 Mn |
| Dec 31, 2024 | -536.54 Mn |
| Sep 30, 2024 | -432.06 Mn |
| Jun 30, 2024 | -469.12 Mn |
| Mar 31, 2024 | -420.67 Mn |
| Dec 31, 2023 | -466.35 Mn |
| Sep 30, 2023 | -496.76 Mn |
| Jun 30, 2023 | -539.10 Mn |
| Mar 31, 2023 | -583.39 Mn |
| Dec 31, 2022 | -616.37 Mn |
| Sep 30, 2022 | -371.82 Mn |
| Jun 30, 2022 | -395.08 Mn |
| Mar 31, 2022 | -364.81 Mn |
| Dec 31, 2021 | -420.17 Mn |
| Sep 30, 2021 | -435.77 Mn |
| Jun 30, 2021 | -458.33 Mn |